Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... for the initiation of the Phase 2b program to evaluate the Company's once-daily inhaled liposomal ciprofloxacin administered via nebulizer in patients with non-cystic fibrosis ...
2009 NOV 16 ... Bio-Path Holdings, Inc. Bio-Path Holdings, Inc. is developing leading-edge, patented, liposomal drug delivery systems developed at The University of Texas M. D. Anderson Cancer Center, ...
2009 NOV 9 ... tumor control and improve quality of life. ThermoDox is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the ...
2009 NOV 23 ... the progress made in the commercialization of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin for the treatment of hepatocellular carcinoma (HCC), the ...
2009 NOV 23 ... and colleagues, Jagiellonian University. The researchers concluded: "The liposomal formulation showed higher than p-THPP-PEG2000 photocytotoxicity towards both cell lines ...
2009 NOV 9 ... to the FDA for the study of liposome entrapped docetaxel (LE-DT), a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, for locally ...
2009 NOV 23 ... malignant glioma xenografts. We have developed a novel, convectable non-PEGylated liposomal formulation that can be used to encapsulate both the topoisomerase I inhibitor topotecan ...
2009 NOV 16 ... "The pharmacokinetics and pharmacodynamics of a novel liposomal amikacin for inhalation were evaluated in cystic fibrosis patients with chronic ...
2009 NOV 9 ... with micafungin, but deteriorated and died, despite his treatment being changed to liposomal amphotericin B. On the basis of this we suggest that IFI caused by L. mutabilis should ...
2009 NOV 16 ... States, "The pharmacokinetics and safety of extended-interval dosing of prophylactic liposomal amphotericin B (L-AMB) in peripheral stem cell transplant recipients were evaluated. The ...
2009 NOV 16 ... "It nonetheless may be considered as an azole option for either follow-up therapy after liposomal amphotericin B therapy or as salvage therapy in patients intolerant of amphotericin B or ...
2009 NOV 23 ... protection was achieved in mice even when the Ag dose was reduced to as low as 280 ng of liposomal peptide. This form of vaccination with a single CTL epitope induced Ag-specific memory ...
2009 NOV 16 ... lack of lung radiological signs could be related to prophylactic treatment with inhaled liposomal amphotericin B, which could have prevented clinically evident Aspergillus lung ...
2009 NOV 23 ... for relieving arthritic and traumatic pain, in this study, a novel brucine-loaded liposomal hydrogel (BLH) formulation, suitable for topical application, was developed. Spherical ...
2009 NOV 9 ... regimens with synergistic activity are sought for. In this phase-I/II trial, pegylated liposomal doxorubicin (Caelyx ™, PEG-Dox) and prolonged administration of Temozolomide in ...
2009 NOV 16 ... c liposomes (CC-F)." "The influence of the preparation components on the liposomal encapsulation efficiency and the stability were studied. The anti-cataract effect of the ...
2009 NOV 23 ... of Texas. The researchers concluded: "Sequential inhalation delivery of liposomal-formulated paclitaxel and a-TEA produces significantly better anti-tumor outcomes than ...
2009 NOV 16 ... sensitive to lipid formulations of amphotericin B (AMB). We examined the effect of the liposomal AMB formulation, AmBisome, and free AMB on the adherence of C. albicans to HeLa cervical ...
2009 NOV 10 ... forms pores faster than wild type Bcl-2. Bcl-2 oligomers were detected in the liposomal membranes under conditions that Bcl-2 forms pores, and the extent of oligomerization was ...
2009 NOV 2 ... positive clinical trial results on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections. The ...
